Centivax
Centivax is dedicated to accelerating the transition to a post-pathogen humanity through the development of innovative vaccines and therapies. Their mission focuses on creating broad-spectrum vaccines and anti-infectives to combat various infectious diseases, including influenza and COVID-19.
Centivax
1 Tower Place, Suite 800, South San Francisco, CA 94080
What We Do
A broad-spectrum vaccine in pre-clinical development for the prevention of all influenza, awarded a Gates Foundation Grand Challenge.
A universal vaccine that has completed pre-clinical development and is scheduled for human clinical trials to begin in 2025, also awarded a Gates Foundation Grand Challenge.
Broad-Spectrum Anti-Infectives
Development of universal vaccines and broad-spectrum antibody programs to combat multidrug-resistant bacteria, supported by various medical research institutions.
Infectious Diseases
Key People
Sawsan Youssef
Chief Science Officer
Nicholas Bayless
Chief Medical Officer
David Tsao
Chief Business Officer
Stephanie Wisner
Chief Operating Officer
Jerald Sadoff
Chief Technology Officer
Funded Projects
Centivax’s Novel Engineered Antibody Neutralizes Pandemic Coronaviruses and has been Engineered for Enhanced Therapeutic Properties
With support from MTEC, Centivax has rapidly developed a potent antibody therapeutic for COVID-19 in under nine weeks. Engineered for safety, stability, and field deployment, the treatment has completed preclinical studies and is advancing toward clinical trials to address both military and civilian healthcare needs.
News & Updates
An article discussing Centivax's efforts to combat COVID-19 variants through antibody development.
Centivax CEO emphasizes the importance of widespread vaccination to prevent COVID-19 mutations.
Discussion on strategies to combat COVID-19 amidst the emergence of the Omicron variant.
An article exploring the shift in focus towards COVID-19 therapeutics by a prominent figure from the Netflix docuseries.
Highlighting Stephanie Wisner's recognition in Forbes 30 Under 30 for her contributions to Centivax.